194 related articles for article (PubMed ID: 38256864)
1. Illuminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria.
Madigan KE; Rudnick SR; Agnew MA; Urooj N; Bonkovsky HL
Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38256864
[TBL] [Abstract][Full Text] [Related]
2. How I treat erythropoietic protoporphyria and X-linked protoporphyria.
Leaf RK; Dickey AK
Blood; 2023 Jun; 141(24):2921-2931. PubMed ID: 36898083
[TBL] [Abstract][Full Text] [Related]
3. Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria.
Di Pierro E; Granata F; De Canio M; Rossi M; Ricci A; Marcacci M; De Luca G; Sarno L; Barbieri L; Ventura P; Graziadei G
Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054318
[TBL] [Abstract][Full Text] [Related]
4. Congenital erythropoietic porphyria and erythropoietic protoporphyria: Identification of 7 uroporphyrinogen III synthase and 20 ferrochelatase novel mutations.
Weiss Y; Balwani M; Chen B; Yasuda M; Nazarenko I; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):358-362. PubMed ID: 30454868
[TBL] [Abstract][Full Text] [Related]
5. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria.
Balwani M; Doheny D; Bishop DF; Nazarenko I; Yasuda M; Dailey HA; Anderson KE; Bissell DM; Bloomer J; Bonkovsky HL; Phillips JD; Liu L; Desnick RJ;
Mol Med; 2013 Apr; 19(1):26-35. PubMed ID: 23364466
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.
Balwani M
Mol Genet Metab; 2019 Nov; 128(3):298-303. PubMed ID: 30704898
[TBL] [Abstract][Full Text] [Related]
7. Dersimelagon in Erythropoietic Protoporphyrias.
Balwani M; Bonkovsky HL; Levy C; Anderson KE; Bissell DM; Parker C; Takahashi F; Desnick RJ; Belongie K;
N Engl J Med; 2023 Apr; 388(15):1376-1385. PubMed ID: 37043653
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.
Balwani M; Naik H; Anderson KE; Bissell DM; Bloomer J; Bonkovsky HL; Phillips JD; Overbey JR; Wang B; Singal AK; Liu LU; Desnick RJ
JAMA Dermatol; 2017 Aug; 153(8):789-796. PubMed ID: 28614581
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of oral iron therapy in erythropoietic protoporphyria and X-linked protoporphyria.
Balwani M; Naik H; Overbey JR; Bonkovsky HL; Bissell DM; Wang B; Phillips JD; Desnick RJ; Anderson KE
Mol Genet Metab Rep; 2022 Dec; 33():100939. PubMed ID: 36406817
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietic protoporphyria.
Lecha M; Puy H; Deybach JC
Orphanet J Rare Dis; 2009 Sep; 4():19. PubMed ID: 19744342
[TBL] [Abstract][Full Text] [Related]
11. Delta-aminolevulinic acid synthase 2 expression in combination with iron as modifiers of disease severity in erythropoietic protoporphyria.
Barman-Aksözen J; Halloy F; Iyer PS; Schümperli D; Minder AE; Hall J; Minder EI; Schneider-Yin X
Mol Genet Metab; 2019 Nov; 128(3):304-308. PubMed ID: 31076252
[TBL] [Abstract][Full Text] [Related]
12. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability.
Barman-Aksözen J; Minder EI; Schubiger C; Biolcati G; Schneider-Yin X
Blood Cells Mol Dis; 2015 Jan; 54(1):71-7. PubMed ID: 25179834
[TBL] [Abstract][Full Text] [Related]
13. Cimetidine for erythropoietic protoporphyria.
Heerfordt IM; Lerche CM; Wulf HC
Photodiagnosis Photodyn Ther; 2022 Jun; 38():102793. PubMed ID: 35245673
[TBL] [Abstract][Full Text] [Related]
14. Homeostasis of iron and hepcidin in erythropoietic protoporphyria.
Bossi K; Lee J; Schmeltzer P; Holburton E; Groseclose G; Besur S; Hwang S; Bonkovsky HL
Eur J Clin Invest; 2015 Oct; 45(10):1032-41. PubMed ID: 26199063
[TBL] [Abstract][Full Text] [Related]
15. Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist.
Ogasawara A; Ogawa K; Ide R; Ikenaga Y; Fukunaga C; Nakayama S; Tsuda M
Eur J Clin Pharmacol; 2023 Jun; 79(6):801-813. PubMed ID: 37060458
[TBL] [Abstract][Full Text] [Related]
16. [Inheritance in erythropoietic protoporphyria].
Schmitt C; Ducamp S; Gouya L; Deybach JC; Puy H
Pathol Biol (Paris); 2010 Oct; 58(5):372-80. PubMed ID: 20850938
[TBL] [Abstract][Full Text] [Related]
17. Experimental and approved treatments for skin photosensitivity in individuals with erythropoietic protoporphyria or X-linked protoporphyria: A systematic review.
Heerfordt IM; Lerche CM; Philipsen PA; Wulf HC
Biomed Pharmacother; 2023 Feb; 158():114132. PubMed ID: 36525819
[TBL] [Abstract][Full Text] [Related]
18. X-linked dominant protoporphyria: The first reported Japanese case.
Ninomiya Y; Kokunai Y; Tanizaki H; Akasaka E; Nakano H; Moriwaki S
J Dermatol; 2016 Apr; 43(4):414-8. PubMed ID: 26387792
[TBL] [Abstract][Full Text] [Related]
19. Advances in the management of erythropoietic protoporphyria - role of afamelanotide.
Lane AM; McKay JT; Bonkovsky HL
Appl Clin Genet; 2016; 9():179-189. PubMed ID: 28003770
[TBL] [Abstract][Full Text] [Related]
20. Heme Biosynthetic Gene Expression Analysis With dPCR in Erythropoietic Protoporphyria Patients.
Granata F; Brancaleoni V; Barman-Aksözen J; Scopetti M; De Luca G; Fustinoni S; Motta I; Di Pierro E; Graziadei G
Front Physiol; 2022; 13():886194. PubMed ID: 35923227
[No Abstract] [Full Text] [Related]
[Next] [New Search]
